Recruiting

Netarsudil

Sponsor:

Indiana University

Code:

NCT07588152

Conditions

Glaucoma

Ocular Hypertension

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Netarsudil Ophthalmic Solution (Rhopressa)

Artificial Tears (AT)

Study Details

Brief summary:

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.

Conditions

Glaucoma

Ocular Hypertension

Study ID

NCT07588152

Start date

Jun 5, 2026

Status verified date

Jun, 2026

Completion date

Jun, 2028

Anticipated

Primary completion date

Jun, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults aged 18 years or older
  • Diagnosis of ocular hypertension or open-angle glaucoma
  • Eye examination within the past year
  • For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma
  • Best-corrected visual acuity of 20/100 or better
  • Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)
  • Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)

Exclusion Criteria:

  • Known intolerance to netarsudil ophthalmic solution
  • Corneal scarring or active corneal disease that would interfere with imaging
  • Inability to tolerate gonioscopy procedures
  • Females of childbearing potential who are not using effective contraception or are not sterile
  • Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Netarsudil (Rhopressa)

Participants will receive netarsudil ophthalmic solution administered as one drop in the study eye once daily in the evening for approximately 14 days.

placebo comparator: Placebo (Artificial Tears)

Participants will receive artificial tears administered as one drop in the study eye once daily in the evening for approximately 14 days.

Interventions

Netarsudil Ophthalmic Solution (Rhopressa)

Netarsudil ophthalmic solution is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, it will be administered once daily in the evening for approximately 14 days.

Artificial Tears (AT)

Artificial tears will be used as a placebo control and administered once daily in the evening for approximately 14 days. These drops are not expected to lower intraocular pressure or alter trabecular meshwork structure.

Primary outcome measure

  • Change in Trabecular Meshwork Lamellae Spacing [ Time Frame: Baseline to 14-21 days after initiation of treatment ]

Central Contacts and Locations

Central contacts

Brett J King, OD

(812) 855-1344kingbrj@iu.edu

Locations

Indiana Universtiy School of Optometry

Recruiting

Bloomington, Indiana, United States, 47405

More Information

Sponsor

Indiana University

Last update posted

Jun 11, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Indiana University on 2026-06-11.